Joint Venture with Shenzhen Hepalink Pharmaceutical Co., Ltd

China-based global pharmaceutical focusing on the development of combination immunotherapy for the China market

The creation of OncoVent will provide additional resources for product development that OncoQuest can access to accelerate its worldwide product registration strategy. OncoVent will focus on the development, manufacturing and commercialization of Cancer Immunotherapy Products within China with pancreatic cancer as its first target.